<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675714</url>
  </required_header>
  <id_info>
    <org_study_id>04-157</org_study_id>
    <secondary_id>NIDILRR 90DP0043-03-00</secondary_id>
    <secondary_id>P50GM060338</secondary_id>
    <nct_id>NCT00675714</nct_id>
  </id_info>
  <brief_title>Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation</brief_title>
  <official_title>Assessment of the Treatment of the Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Department of Education</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the program is to study and characterize the outcome of burn injury with
      particular attention to improving the rehabilitation of burn survivors, including children.
      Various agents are assessed for effectiveness on long term burn outcome, such as growth
      hormone, oxandrolone, propranolol,ketoconazole, inhospital exercise and home exercise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The University of Texas Medical Branch(UTMB) project improves outcomes for severely burned
      children by instituting and evaluating two modifications to traditional rehabilitation: (1)
      an intensive rehabilitation program including active resistance exercise; (2) long term
      administration of anabolic agents.

      Effectiveness is assessed by comparison with functional outcomes achieved in traditional
      outpatient rehabilitation programs. Results indicate improvement in strength, endurance and
      bone density with these modifications. The project also maintains a longitudinal database
      that includes measures of cardiopulmonary function, growth and maturation, bone density,
      range of motion, and psychosocial adjustment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome assessments will include measures of muscle wasting, weakness, immunosuppression chronic bone loss and decreased growth with increases in metabolic, hemodynamic, inflammatory and scarring responses.</measure>
    <time_frame>Admission to burn unit and up to 2 years post burn and yearly after that</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Humatrope subcutaneous(SQ) 0.05-0.2 mg/kg/day for up to 2 years post burn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketoconazole by mouth (PO) given twice a day throughout hospitalization for up to 2 years post burn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxandrolone PO given daily throughout hospitalization for up to 2 years post burn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol PO given daily throughout hospitalization for up to 2 years post burn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxandrolone and propranolol PO to be given daily for up to 2 years post burn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Humatrope SQ and Propranolol PO to be given daily for up to 2 years post burn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo PO to be given for up to 2 years post burn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise--hospital supervised intensive exercise program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise--home or community based exercise program</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stable Isotope Infusion Study</intervention_name>
    <description>1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of blood and tissues</intervention_name>
    <description>Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI</intervention_name>
    <description>Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humatrope</intervention_name>
    <description>Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>recombinant human growth hormone</other_name>
    <other_name>GH</other_name>
    <other_name>rhGH</other_name>
    <other_name>Growth Hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury</description>
    <arm_group_label>2</arm_group_label>
    <other_name>itraconazole</other_name>
    <other_name>fluconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxandrolone</intervention_name>
    <description>oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury</description>
    <arm_group_label>3</arm_group_label>
    <other_name>testosterone</other_name>
    <other_name>nandrolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>metroprolol</other_name>
    <other_name>inderol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxandrolone and propranolol combined</intervention_name>
    <description>Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.</description>
    <arm_group_label>5</arm_group_label>
    <other_name>testosterone</other_name>
    <other_name>nandrolone</other_name>
    <other_name>inderol</other_name>
    <other_name>metoprolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humatrope and propranolol combined</intervention_name>
    <description>Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.</description>
    <arm_group_label>6</arm_group_label>
    <other_name>recombinant human growth hormone</other_name>
    <other_name>GH</other_name>
    <other_name>rhGH</other_name>
    <other_name>inderol</other_name>
    <other_name>metoprolol</other_name>
    <other_name>growth hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to be given once a day for up to two years post burn injury.</description>
    <arm_group_label>7</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise--Hospital supervised intensive exercise program</intervention_name>
    <description>intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.</description>
    <arm_group_label>8</arm_group_label>
    <other_name>exercise</other_name>
    <other_name>intensive exercise</other_name>
    <other_name>aerobic exercise</other_name>
    <other_name>exercise rehabilitation program</other_name>
    <other_name>hospital based exercise</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Home exercise program</intervention_name>
    <description>Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.</description>
    <arm_group_label>9</arm_group_label>
    <other_name>Home exercise</other_name>
    <other_name>intensive exercise</other_name>
    <other_name>exercise rehabilitation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burn 30% Total Body Surface Area (TBSA) or greater

          -  Ages 0-80 yrs

          -  Negative pregnancy test

          -  Informed consent

        Exclusion Criteria:

          -  Untreated malignancy, known history of AIDS, ARC, HIV

          -  Recent history of myocardial infarction (6 wks)

          -  Tuberculosis, arthritis, cirrhosis, hyperlipidemia, bone or endocrine diseases,
             autoimmune diseases

          -  Chronic glucocorticoid or non steroidal anti inflammatory drug therapy

          -  Diabetes mellitus prior to burn injury

          -  Renal insufficiency (defined by creatinine &gt;3.0 mg/dl)

          -  Hepatic disease (bilirubin &gt; 3.0 mg/dl)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Herndon, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David N Herndon, MD</last_name>
    <phone>409-770-6731</phone>
    <email>dherndon@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cathy L Reed, BSN</last_name>
    <phone>409-770-6987</phone>
    <email>ca2reed@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David N Herndon, MD</last_name>
      <phone>409-770-6731</phone>
      <email>dherndon@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cathy L Reed, BSN</last_name>
      <phone>409-770-6987</phone>
      <email>ca2reed@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David N Herndon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar E Suman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celeste FInnerty, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.utmb.edu/sbhnidrr/</url>
    <description>University of Texas web page to describe funded program</description>
  </link>
  <link>
    <url>http://www.totalburncare.com</url>
    <description>burn care web site includes information on funded grant project</description>
  </link>
  <reference>
    <citation>Alloju SM, Herndon DN, McEntire SJ, Suman OE. Assessment of muscle function in severely burned children. Burns. 2008 Jun;34(4):452-9. doi: 10.1016/j.burns.2007.10.006. Epub 2008 Feb 20.</citation>
    <PMID>18243565</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anabolic agents</keyword>
  <keyword>exercise</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Oxandrolone</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
    <mesh_term>Nandrolone decanoate</mesh_term>
    <mesh_term>Nandrolone phenpropionate</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Anabolic Agents</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

